Skip to main content

Table 1 Mortality rate, hypertension prevalence, RR for death, disease severity, and ICU admission among COVID-19 patients

From: Prevalence of hypertension and associated risks in hospitalized patients with COVID-19: a meta-analysis of meta-analyses with 1468 studies and 1,281,510 patients

Variable

Last date of search (month)

Number of studies

Summary estimates (prevalence/RR) [95% CI]

Heterogeneity (I2 %)

Publication bias-Egger test (P value)

Mortality rate

March

5

12% [7–17%]

99.3

N/A

April

6

13% [7–19%]

99.9

N/A

May

5

10% [2–18%]

99.9

N/A

July

1

24% [24–25%]

0.00

N/A

Overall

17

12% [9–16%]

99.9

N/A

Hypertension prevalence

February

3

20% [17–22%]

86

N/A

March

7

20% [15–25%]

99.3

N/A

April

13

25% [19–32%]

99.9

N/A

May

7

24% [17–31%]

99.9

N/A

June

2

29% [23–35%]

99.6

N/A

July

4

36% [26–47%]

99.8

N/A

Overall

36

25% [22–28%]

99.9

N/A

RR for death

March

2

2.22 [1.47–2.98]

0.00

0.001

April

8

1.84 [1.62–2.05]

77.8

May

6

1.88 [1.74–2.02]

0.00

June

1

1.83 [1.63–2.03]

July

2

1.78 [1.45–2.11]

0.00

September

1

1.74 [1.41–2.08]

November

1

1.49 [1.35–1.63]

-

Overall

21

1.79 [1.68–1.89]

61.5

RR for disease severity

February

3

1.87 [1.63–2.11]

0.00

0.007

March

7

1.72 [1.45–1.99]

50.2

April

10

1.77 [1.62–1.93]

31.5

May

4

1.89 [1.63–2.15]

0.00

July

2

1.62 [1.25–2.00]

0.00

Overall

30

1.74 [1.66–1.83]

27.7

RR for ICU admissiona

Overall

5

1.91 [1.48–2.34]

74.9

0.462

  1. CI Confidence Interval
  2. aDue to the small number of studies in this section, the subgroup analysis was not performed